Drugs / PEC210A
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05210530 | Jan 2022 → Jan 2023 | type 1 diabetes mellitus | CRISPR Therapeutics AG | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PEC210A | “allogeneic pancreatic endoderm cells (PEC210A) genetically modified using Clustered Regularly Interspaced Short Palindromic Repeats/CRISPR-associated protein 9 (CRISPR/Cas9) to...” NCT05210530 ↗ |
| Modality | Cell therapy | “CRISPR-Cas9 genetically modified PEC210A cells loaded into a delivery device” NCT05210530 ↗ |
| Route | Other | “Up to seven (7) units will be implanted” NCT05210530 ↗ |